TY - JOUR
T1 - Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis
AU - Colalillo, Amalia
AU - Hachulla, Eric
AU - Pellicano, Chiara
AU - Smith, Vanessa
AU - Bergmann, Christina
AU - Riemekasten, Gabriela
AU - Zanatta, Elisabetta
AU - Henes, Jörg
AU - Launay, David
AU - Marcoccia, Antonella
AU - Gheorghiu, Ana Maria
AU - Truchetet, Marie Elise
AU - Iannone, Florenzo
AU - Simeón Aznar, Carmen Pilar
AU - Oliveira, Susana
AU - Vonk, Madelon
AU - Del Galdo, Francesco
AU - Rosato, Edoardo
AU - Distler, Oliver
AU - Becker, Mike
AU - De Decker, Melissa
AU - Fegatelli, Danilo Alunni
AU - Siegert, Elise
AU - Castellví, Ivan
AU - Cauli, Alberto
AU - Solanki, Kamal
AU - Dagna, Lorenzo
AU - Martin, Mickaël
AU - Moroncini, Gianluca
AU - Poormoghim, Hadi
AU - Kuwana, Masataka
AU - Carreira, Patricia E.
AU - Airò, Paolo
AU - Spierings, Julia
AU - Tanaka, Yoshiya
AU - Selvi, Enrico
AU - Soukup, Tomas
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024/10
Y1 - 2024/10
N2 - Background: The 2022 European Society of Cardiology/European Respiratory Society guidelines define pulmonary hypertension (PH) as a resting mean pulmonary artery pressure (mPAP) > 20 mm Hg at right heart catheterization (RHC). Previously, patients with an mPAP between 21 and 24 mm Hg were classified in a “gray zone” of unclear clinical significance. Research Question: What is the diagnostic performance of the main parameters used for PH screening in detecting patients with systemic sclerosis (SSc) with an mPAP of 21 to 24 mm Hg at RHC? Study Design and Methods: Patients with SSc from the European Scleroderma Trials and Research (EUSTAR) database with available tricuspid annular plane systolic excursion (TAPSE), systolic PAP (sPAP), and mPAP data were included. Patients with mPAP 21 to 24 mm Hg and patients with mPAP ≤ 20 mm Hg were considered for the analysis. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated. Results: TAPSE/sPAP was lower in the group of patients with SSc with mPAP 21 to 24 mm Hg than in the non-PH group (0.58 [0.46-0.72] vs 0.69 [0.57-0.81] mm/mm Hg, respectively; P < .01). No difference was found in other parameters between the two groups. Diffusing capacity of the lungs for carbon monoxide < 80% of the predicted value had the highest sensitivity (88.9%) and NPV (80%), but the lowest specificity (18.2%) and PPV (30.8%) in detecting patients with SSc with mPAP 21 to 24 mm Hg. TAPSE/sPAP < 0.55 mm/mm Hg had the highest specificity (78.9%), PPV (50%), and accuracy (68.1%); its NPV was 75.4%, and its sensitivity was 45.1%. Interpretation: In this study, diffusing capacity of the lungs for carbon monoxide < 80% of the predicted value was the parameter with the highest sensitivity and NPV in detecting patients with SSc with mPAP 21 to 24 mm Hg. TAPSE/sPAP < 0.55 mm/mm Hg had the highest specificity, PPV, and accuracy and, therefore, can be a useful additional parameter to decrease the number of unnecessary RHCs.
AB - Background: The 2022 European Society of Cardiology/European Respiratory Society guidelines define pulmonary hypertension (PH) as a resting mean pulmonary artery pressure (mPAP) > 20 mm Hg at right heart catheterization (RHC). Previously, patients with an mPAP between 21 and 24 mm Hg were classified in a “gray zone” of unclear clinical significance. Research Question: What is the diagnostic performance of the main parameters used for PH screening in detecting patients with systemic sclerosis (SSc) with an mPAP of 21 to 24 mm Hg at RHC? Study Design and Methods: Patients with SSc from the European Scleroderma Trials and Research (EUSTAR) database with available tricuspid annular plane systolic excursion (TAPSE), systolic PAP (sPAP), and mPAP data were included. Patients with mPAP 21 to 24 mm Hg and patients with mPAP ≤ 20 mm Hg were considered for the analysis. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated. Results: TAPSE/sPAP was lower in the group of patients with SSc with mPAP 21 to 24 mm Hg than in the non-PH group (0.58 [0.46-0.72] vs 0.69 [0.57-0.81] mm/mm Hg, respectively; P < .01). No difference was found in other parameters between the two groups. Diffusing capacity of the lungs for carbon monoxide < 80% of the predicted value had the highest sensitivity (88.9%) and NPV (80%), but the lowest specificity (18.2%) and PPV (30.8%) in detecting patients with SSc with mPAP 21 to 24 mm Hg. TAPSE/sPAP < 0.55 mm/mm Hg had the highest specificity (78.9%), PPV (50%), and accuracy (68.1%); its NPV was 75.4%, and its sensitivity was 45.1%. Interpretation: In this study, diffusing capacity of the lungs for carbon monoxide < 80% of the predicted value was the parameter with the highest sensitivity and NPV in detecting patients with SSc with mPAP 21 to 24 mm Hg. TAPSE/sPAP < 0.55 mm/mm Hg had the highest specificity, PPV, and accuracy and, therefore, can be a useful additional parameter to decrease the number of unnecessary RHCs.
KW - diffusing capacity of the lungs for carbon monoxide
KW - pulmonary hypertension
KW - screening
KW - systemic sclerosis
KW - tricuspid annular plane systolic excursion/systolic pulmonary arterial pressure
UR - http://www.scopus.com/inward/record.url?scp=85203533892&partnerID=8YFLogxK
U2 - 10.1016/j.chest.2024.05.010
DO - 10.1016/j.chest.2024.05.010
M3 - Article
C2 - 38849072
AN - SCOPUS:85203533892
SN - 0012-3692
VL - 166
SP - 837
EP - 844
JO - Chest
JF - Chest
IS - 4
ER -